Hyperlink

Enhanced Hyundai 2025 Santa Cruz Makes World Debut at the New York International Auto Show

Retrieved on: 
Wednesday, March 27, 2024
American Express, OTA, Visa, DCT, Humanity, BVM, SUV, Acceleration, Hyundai Motor America, Hyundai Motor Company, SVM, GPS, Condition, HTRAC, Mastercard, Turbocharger, Torque, Telecommunications, Multimedia, Map, Hyperlink

Santa Cruz also offers a 2.5L direct-injected turbocharged engine with 281 horsepower and 311 lb.-ft. of torque linked to an eight-speed wet dual-clutch automatic transmission (DCT).

Key Points: 
  • Santa Cruz also offers a 2.5L direct-injected turbocharged engine with 281 horsepower and 311 lb.-ft. of torque linked to an eight-speed wet dual-clutch automatic transmission (DCT).
  • The eight-speed transmission for the standard 2.5-liter engine provides quick and crisp shifts for an engaging and efficient driving experience.
  • The Sport setting gives Santa Cruz a more agile feel by sending additional torque to the rear wheels, for a sporty, dynamic experience.
  • Hyundai Motor America offers U.S. consumers a technology-rich lineup of cars, SUVs, and electrified vehicles, while supporting Hyundai Motor Company's Progress for Humanity vision.

Tequity Advises SaaS Supply Chain ERP Provider, Blue Link Associates, on Strategic Acquisition by Cordance

Retrieved on: 
Monday, January 22, 2024
Cloud, Supply, Professional, E-commerce, Shopify, Food, Software as a service, Entrepreneurship, USDA, Software, Sale, Acquisition, Safety, FDA, Hyperlink, Government, Health Canada, Pleasure, Growth, Asset management

TORONTO, Jan. 22, 2024 /PRNewswire/ -- Tequity, a leading North American M&A Advisory firm specializing in global Enterprise B2B SaaS, Cloud, and IT company transactions, acted as the exclusive financial advisor to Blue Link Associates, a leader in SaaS ERP solutions, in their acquisition by Cordance.

Key Points: 
  • This strategic move further solidifies Cordance's commitment to enhancing its portfolio with innovative software solutions that empower businesses across diverse industries.
  • Blue Link ERP isn't just software; it's the foundation of our commitment to efficiency, accuracy, and top-quality service and support."
  • Mark added, "Working with Tequity was a great experience - they know the Supply Chain ERP market and who the potential buyers are here and are experienced in cross-border transactions.
  • This acquisition reflects Cordance's commitment to preserving the unique strength and innovative culture that has made Blue Link a trusted partner for industrial, pharmaceutical and food and beverage distributors.

Immunology Collaboration and Licensing Agreements Analysis Report 2023 with Directory of Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Biotechnology, Pharmaceutical, Health, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Vaccine, Pharmaceutical industry, Cryptocurrency, Publishing, Risk management, Property management, Commercial property, Lease

Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of immunology deals from 2016 to 2023.
  • The report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016.
  • Chapter 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available.

Global Hospital Care Collaboration and Licensing Agreements Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Health, Hospitals, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Nursing, Cryptocurrency, Publishing, Risk management, Property management, Commercial property, Lease

Fully revised and updated, the report provides details of hospital care deals from 2016 to 2023.

Key Points: 
  • Fully revised and updated, the report provides details of hospital care deals from 2016 to 2023.
  • Hospital Care Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hospital care deals entered into by the worlds leading biopharma companies.
  • The report also includes numerous table and figures that illustrate the trends and activities in hospital care deal making since 2016.
  • Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in hospital care dealmaking.

Autoimmune Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Biotechnology, Pharmaceutical, Health, Chapter Six, Chapter, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Collaboration, Cryptocurrency, Health insurance

Fully revised and updated, the report provides details of autoimmune deals from 2016 to 2023.

Key Points: 
  • Fully revised and updated, the report provides details of autoimmune deals from 2016 to 2023.
  • Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma companies.
  • The report also includes numerous table and figures that illustrate the trends and activities in autoimmune deal making since 2016.
  • Chapter 5 provides a comprehensive and detailed review of autoimmune deals signed and announced since 2016 where a contract document is available.

Dermatology Collaboration and Licensing Deals Analysis Report and Directory 2016-2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Biotechnology, Pharmaceutical, Health, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Dermatology, Orientation, Chapter Three, Chapter One, Veterinary medicine, Commercial property, Cryptocurrency, Publishing, Risk management, Property management, Lease

The "Dermatology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dermatology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.
  • Fully revised and updated, the report provides details of dermatology deals from 2016 to 2023.
  • Dermatology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the dermatology deals entered into by the worlds leading biopharma companies.
  • Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in dermatology dealmaking.

Ophthalmics Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of Deals Signed by the World's Leading Biopharma Companies Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Health, Optical, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Pharmaceutical industry, Cryptocurrency, Publishing, Risk management, Property management, Commercial property, Lease

Fully revised and updated, the report provides details of ophthalmics deals from 2016 to 2023.

Key Points: 
  • Fully revised and updated, the report provides details of ophthalmics deals from 2016 to 2023.
  • Ophthalmics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the ophthalmics deals entered into by the worlds leading biopharma companies.
  • The report also includes numerous table and figures that illustrate the trends and activities in ophthalmics deal making since 2016.
  • Chapter 5 provides a comprehensive and detailed review of ophthalmics deals signed and announced since 2016 where a contract document is available.

Hematology Collaboration and Licensing Agreements Analysis Report 2023: Access to Deals Signed by the World's Leading Biopharma Companies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 22, 2023
Biotechnology, Pharmaceutical, Health, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Commercial property, Cryptocurrency, Publishing, Risk management, Property management, Lease

Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of hematology deals from 2016 to 2023.
  • The report also includes numerous table and figures that illustrate the trends and activities in hematology deal making since 2016.
  • Chapter 3 covers the financial deal terms for deals signed in the hematology field with stage of development announced.

Microbiome Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of 233 Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 22, 2023
Biotechnology, Pharmaceutical, Health, Record, Research, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Orientation, Chapter Three, Directory, Chapter One, Antibiotics, Risk management, Real estate, Property management, Commercial property, Lease

Microbiome Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the microbiome deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Microbiome Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the microbiome deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of microbiome deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter microbiome deals.
  • The report also includes numerous table and figures that illustrate the trends and activities in microbiome deal making since 2016.

Respiratory Collaboration and Licensing Agreements Report 2023: Unprecedented Access to Deals Entered into by the Worlds Leading Biopharma Companies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 22, 2023
Biotechnology, Pharmaceutical, Health, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Commercial property, Cryptocurrency, Publishing, Risk management, Property management, Lease

Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of respiratory deals from 2016 to 2023.
  • The report also includes numerous table and figures that illustrate the trends and activities in respiratory deal making since 2016.
  • Chapter 3 covers the financial deal terms for deals signed in the respiratory field with stage of development announced.